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Abstract
Background: Multiple medications is a well-known potential risk factor in terms of patient's
health. The aim of the present study was to estimate the prevalence of dispensed drugs and multiple
medications in an entire national population, by using individual based data on dispensed drugs.
Methods: Analyses of all dispensed out-patient prescriptions in 2006 from the Swedish prescribed
drug register. As a cut-off for multiple medications, we applied five or more different drugs
dispensed (DP ≥ 5) at Swedish pharmacies for a single individual during a 3-month, a 6-month, and
a 12-month study period. For comparison, results were also calculated with certain drug groups
excluded.
Results: 6.2 million individuals received at least one dispensed drug (DP ≥ 1) during 12 months in
2006 corresponding to a prevalence of 67.4%; 75.6% for females and 59.3% for males. Individuals
received on average 4.7 dispensed drugs per individual (median 3, Q1–Q3 2–6); females 5.0
(median 3, Q1–Q3 2–7), males 4.3 (median 3, Q1–Q3 1–6).
The prevalence of multiple medications (DP ≥ 5) was 24.4% for the entire population. The
prevalence increased with age. For elderly 70–79, 80–89, and 90-years, the prevalence of DP ≥ 5
was 62.4, 75.1, and 77.7% in the respective age groups. 82.8% of all individuals with DP ≥ 1 and
64.9% of all individuals with DP ≥ 5 were < 70 years.
Multiple medications was more frequent for females (29.6%) than for males (19.2%). For individuals
10 to 39 years, DP ≥ 5 was twice as common among females compared to males. Sex hormones
and modulators of the genital system excluded, reduced the relative risk (RR) for females vs. males
for DP ≥ 5 from 1.5 to 1.4.
The prevalence of DP ≥ 1 increased from 45.1 to 56.2 and 67.4%, respectively, when the study
period was 3, 6, and 12 respectively months and the corresponding prevalence of DP ≥ 5 was 11.3,
17.2, and 24.4% respectively.
Conclusion: The prevalence of dispensed drugs and multiple medications were extensive in all age
groups and were higher for females than for males. Multiple medications should be regarded as a
risk in terms of potential drug-drug interactions and adverse drug reactions in all age groups.
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Background
The total sale of drugs has increased successively during
the last decades [1,2]. The increase depends, among other
things, on the introduction of new medications and on
new medical recommendations to treat morbidity in
higher ages. Moreover, drugs are also used to prevent
health-related disorders among healthy individuals [3].
On a national level, the vast majority of all medications
are dispensed drugs, but over-the-counter drugs (OTC),
vitamins, herbal, alternative remedies, and in-hospital
medications do all contribute to the total drug consump-
tion.
The individuals' use of several different drugs, the so-
called multiple medications, has also increased [4-6]. The
use of many drugs may be rational for many individuals.
However, multiple medications is also commonly associ-
ated with an irrational, excessive use of drugs, and are,
concomitantly taken, a well-known risk factor in terms of
patient's health [4,7,8]. Furthermore, the risk of drug-drug
interactions and adverse drug reactions is expected to
increase exponentially with the number of drugs [9].
Multiple medications may also result in an unnecessary
health expenditure [8], directly due to redundant drug
sales and indirectly due to the increased hospitalization
caused by drug-related problems [10]. Drug-related prob-
lems are reported to cause between 10 and 20% of all
emergency cases in hospitals and up to 20% of all admis-
sions to hospitals of elderly patients [7,11].
Studies of multiple medications have mainly been based
on small samples of elderly individuals admitted to hos-
pitals or nursing homes [8]. A few studies have been based
on population-based information [8,12,13], but some of
these studies have also been limited to elderly individuals
[14-17]. Therefore, it is uncertain to what extent multiple
medications are relevant for other age groups too.
The establishing of the Swedish prescribed drug register in
2005 made it possible to use individual data to explore
and analyse the utilisation of dispensed drugs and multi-
ple medications for an entire national population. Fur-
thermore, the register made it possible to compare
different validated methods of estimating prevalence of
multiple medications from large databases; 3-month
prevalence [8], 6-month prevalence [18], and 12-month
prevalence [19,20].
Aim of the study
The aim of the present study was to estimate the preva-
lence of dispensed drugs and multiple medications in an
entire national population, by using individual based
data on dispensed drugs.
Methods
To estimate the extent of multiple medications in a
national population, we studied the individual based data
of dispensed prescription drugs in the entire Swedish pop-
ulation between January 1, 2006 and December 31, 2006.
The data was extracted from the Swedish prescribed drug
register [13].
As a definition for the individual drug use, we applied one
or more dispensed prescription drugs during a 12-month
period (DP ≥ 1). The prevalence of drug use was conse-
quently defined as the proportion of individuals who
received one or more dispensed drugs during a 12-month
period.
As a cut-off for multiple medications, we applied five or
more dispensed prescription drugs during a 12-month
period (DP ≥ 5). Since five or more drugs is one of the
most commonly used definitions of polypharmacy and
multiple medications [15,21], it might enable compari-
sons with other studies. Consequently, the prevalence of
multiple medications was defined as the proportion of
individuals who received five or more dispensed drugs
during a 12-month period.
For comparison, we studied two shorter study periods; a
3-month period (1 Jan – 31 Mars 2006), and a 6-month
period (1 Jan – 30 June 2006). Furthermore, we also cal-
culated the prevalence when certain drug groups were
excluded; Sex hormones, Antibacterials for systemic use,
and Psycholeptics.
Another concept related to multiple medications is polyp-
harmacy, which means the administration of many drugs
at the same time or the administration of an excessive
number of drugs [22]. The two terms are sometimes over-
lapping. The clinical implications of the two terms are that
multiple medications, when measured as period preva-
lence, can include continuous use, when needed and
short periods of drug use. Polypharmacy should only be
related to concomitant drug use, but is also often meas-
ured as a period prevalence. Whether any number of dis-
pensed drugs is relevant as a measure of polypharmacy in
a clinical perspective is under debate [21,23]. In relation
to polypharmacy, multiple medications (DP ≥ 5) is a
period prevalence measurement, yielding a sum of the
individual's dispensed drugs during a specific period with-
out taking into account the concurrency or the appropri-
ateness of the drug use.
The Swedish prescribed drug register is individual-based
and contains data from dispensed out-patient prescrip-
tions at all Swedish pharmacies from July 1, 2005, includ-
ing multi-dose dispensed prescriptions and legal Internet
sales. The registration is mandatory and the followingBMC Clinical Pharmacology 2009, 9:11 http://www.biomedcentral.com/1472-6904/9/11
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data from the register were employed in our study: dis-
pensed drug (substance), date of dispensing, age, gender,
and a unique identifier (personal identification number)
of the patient.
The prescribed drug register covers the entire Swedish
population (patient identity data is missing for < 0.3% of
all dispensed drugs) [13] and included in 2006 82% of all
defined daily doses (DDD) distributed in Sweden. The
register does not include data on OTC medications
(13%), in-hospital medications (4%), and non-institu-
tional care medications (1% of all DDD) [24]. The register
is not complete for vaccines and for non-dose-dispensed
drugs in nursing homes [13].
All data processing in our study was done anonymously
without the personal identification number. Only gender
and year of birth, originally embedded in the personal
identification number, were recorded. The study popula-
tion was stratified by gender and age (10-year classes). The
results were compared to the number of individuals per
gender and age group in the Swedish population.
Calculation of sums, frequencies and ratios were aggre-
gated using Microsoft Excel (version 5.1.26).
The values applied were the number of individuals and
the number of dispensed prescription drugs. The defini-
tion of drug was the chemical entity or substance compris-
ing the fifth level in the Anatomical Therapeutic Chemical
classification system (ATC). Epidemiological characteris-
tics were defined and applied; prevalence – the proportion
of individuals with five or more dispensed drugs in the
Swedish population during 3-, 6-, and 12-month; relative
risk, (RR) – the ratio between rates in two groups.
The proportion of total drug sales included in the register
was assessed by comparing the data in the register with
information on the total sales of medicines (prescriptions,
OTC, and hospital sales) obtained from the National Cor-
poration of Pharmacies (Apoteket AB).
The study was approved by the Regional Ethical Vetting
Board in Linköping, Sweden.
Results
Prevalence of DP ≥ 1 and DP ≥ 5
Corresponding to 67.4% (6,146,679/9,113,257) of the
entire population, 6.2 million individuals received at least
one dispensed drug (DP ≥ 1) in 2006; 75.6% for females
and 59.3% for males. A total of 2.2 million individuals,
24.4% of the entire population, received five or more dif-
ferent dispensed drugs (DP ≥ 5); 29.6% for females and
19.2% for males (Table 1).
Age and gender of individuals with DP ≥ 1 and DP > 5
The prevalence of DP ≥ 1 was 57.3% in the age group 0–9
and 49.0% in the age group 10–19, subsequently increas-
ing with age to 94.5% in the age group 80–89. DP ≥ 5 also
increased with age, from 6.6% in the age group 0–9 to
77.7% in the age group 90 and above (Table 1) (Figure 1).
82.8% (5,086,701/6,146,679) of all individuals, to whom
at least one drug was dispensed, were less than 70 years of
age. For all individuals, with five or more different drugs,
64.9% (1,446,062/2,227,152) were less than 70 years of
age (Figure 2).
More females than males received at least one dispensed
drug with an RR of 1.3 ((3,466,243/4,589,734)/
Table 1: The prevalence of one or more (DP ≥ 1) and five or more (DP ≥ 5) dispensed drugs related to age and gender. 
DP ≥ 1D P  ≥ 5 RR for females
All Females Males All Females Males DP ≥ 1D P  ≥ 5
Age n = 6,146,679 3,466,243 2,680,436 2,227,152 1,356,934 870,218
0–9 57.3 55.8 58.8 6.6 5.7 7.3 0.9 0.8
10–19 49.0 58.4 40.1 6.2 8.3 4.1 1.5 2.0
20–29 58.4 76.4 41.2 9.9 15.2 5.0 1.8 3.1
30–39 62.5 75.3 50.3 13.9 19.7 8.4 1.5 2.3
40–49 64.3 73.3 55.6 18.4 23.8 13.2 1.3 1.8
50–59 75.8 82.5 69.3 30.2 36.3 24.3 1.2 1.5
60–69 80.1 83.6 76.5 42.3 46.8 37.7 1.1 1.2
70–79 90.8 92.3 89.0 62.4 65.5 58.7 1.0 1.1
80–89 94.5 95.1 93.5 75.1 77.3 71.6 1.0 1.1
90- 93.3 93.6 92.4 77.7 79.4 73.3 1.0 1.1
Total 67.4 75.6 59.3 24.4 29.6 19.2 1.3 1.5
The prevalence (%) of DP ≥ 1 and DP ≥ 5 related to age and gender and the relative risk (RR) for females vs. males with DP ≥ 1 and DP ≥ 5 in 
Sweden in 2006.BMC Clinical Pharmacology 2009, 9:11 http://www.biomedcentral.com/1472-6904/9/11
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(2,680,436/4,523,523)). More females than males also
received DP ≥ 5 with an RR of 1.5 (Table 1).
The RR for females vs. males in terms of receiving five or
more different dispensed drugs increased from 0.8, in the
age group 0–9, to 3.1, in the age group 20–29, followed
by the relative risk successively decreasing; from 2.3 in the
age group 30–39 to 1.1 in the age groups 70 years and
above (Table 1).
The mean number of dispensed drugs specified according 
to gender and age
During the 12-month study period, the mean number of
dispensed drugs for all individuals in Sweden receiving
dispensed drugs was 4.7 (median 3, Q1–Q3 2–6) per
individual; for females 5.0 (median 3, Q1–Q3 2–7), for
males 4.3 (median 3, Q1–Q3 1–6) per individual. For eld-
erly persons, 70 years and above, the mean number of dis-
pensed drugs was 7.9 (median 7, Q1–Q3 4–11), 9.3
(median 8, Q1–Q3 5–13), and 9.7 (median 9, Q1–Q3 6–
13) in the respective age groups; for children 0–9 the
mean number of dispensed drugs was 2.4 (median 2, Q1–
Q3 1–3) (Figure 3).
The impact of the length of the study period on the 
prevalence of DP ≥ 1 and DP ≥ 5
The prevalence of DP ≥ 1 and DP ≥ 5 increased with the
length of the study period. With a study period of 3 and 6
months, the prevalence for DP ≥ 1 were 45.1 and 56.2%,
respectively, and the prevalence of DP ≥ 5 were 11.3 and
17.2%, respectively (Table 2). The study period length
had the greatest impact on the prevalence for the younger
age groups but had a relative minor impact on the preva-
lence for the oldest age groups (Figure 4).
The impact of Sex hormones, Antibacterials for systemic 
use and Psycholeptics on the prevalence of DP ≥ 5
When data on ATC G03 (Sex hormones and modulators
of the genital system) were excluded, the prevalence of DP
≥ 5 for females was reduced from 29.6 to 27.5%. As a con-
sequence, also the prevalence of DP ≥ 5 for all individuals
was reduced, and the RR for DP ≥ 5 for females vs. males
was reduced to 1.4 (Table 2).
The prevalence of one or more (DP ≥ 1) and five or more (DP ≥ 5) dispensed drugs Figure 1
The prevalence of one or more (DP ≥ 1) and five or more (DP ≥ 5) dispensed drugs. The prevalence (%) of DP ≥ 1 
and DP ≥ 5 related to gender and age groups in Sweden in 2006. Number of individuals with DP ≥ 1 = 6,146,679 (females = 
3,466,243 and males = 2,680,436). Number of individuals with DP ≥ 5 = 2,227,152, (females = 1,356,934 and males = 870,218).BMC Clinical Pharmacology 2009, 9:11 http://www.biomedcentral.com/1472-6904/9/11
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When data on ATC J01 (Antibacterials for systemic use)
were excluded, the prevalence of DP ≥ 5 for all individuals
were reduced from 24.4 to 21.9%. In the age group 0–9,
the exclusion of ATC J01 almost dimidiated the preva-
lence of DP ≥ 5, from 6.6 to 3.6%. In the age groups 70
and above, the exclusion of ATC J01 had a relatively
minor effect on DP ≥ 5 (Table 2).
The exclusion of ATC N05 (Psycholeptics) had a marginal
impact on the prevalence of DP ≥ 5 in all age groups
except the age groups 20–29, 30–39, and 40–49 (Table 2).
Discussion
We found that during one year, more then 2/3 of all indi-
viduals in a national population received at least one dis-
pensed drug and that a considerable proportion, about 1/
4, was exposed to multiple medications, a known poten-
tial risk factor for patients' health.
Age and gender
Our findings reveal that multiple medications is not only
a relevant issue regarding the elderly but also for other age
groups. Thus, 2/3 of all individuals with multiple medica-
tions were younger than 70 years of age. Furthermore,
there were more individuals with multiple medications in
the age group 50–59 than in the age group 80–89, and
almost four times as many in the age group 40–49 as in
the age group 90 and above.
Our findings that the median number of dispensed drugs
for all individuals, 70 years and above was 7, 8, and 9 in
the respective 10-year age groups, are in line with previous
reports [15,25].
Multiple medications, being more frequent for females
than for males, may partly be explained by the use of sex
hormones and modulators of the genital system (ATC
G03) among fertile females [26]. When ATC G03 were
excluded from our data, the prevalence of multiple medi-
cations declined in all age groups above 10 years, but the
The number of individuals with and without dispensed drugs related to age Figure 2
The number of individuals with and without dispensed drugs related to age. The total number of individuals related 
to age in Sweden 2006; no dispensed drugs (DP = 0), one to 4 dispensed drugs (DP1–4) and 5 or more dispensed drugs (DP ≥ 
5). Number of individuals = 9,113,257.BMC Clinical Pharmacology 2009, 9:11 http://www.biomedcentral.com/1472-6904/9/11
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RR for females for DP ≥ 5 only decreased from 1.5 to 1.4.
The increased RR among females vs. males for multiple
medications is in line with previous studies [15,27] and
may partly be explained by that females, of all ages, visit a
doctor more often than males [28,29].
The validity of dispensed drugs as an estimator of multiple 
medications
When dispensed drugs are used as an estimator of drug
use and multiple medications, some conditions could
cause both over- and underestimations. For a variety of
reasons, a certain percentage of all drugs will never be
used by patients, resulting in an overestimation of drug
use when studying dispensed drugs [26]. On the reverse,
the prevalence of drug use and multiple medications may
be underestimated, as patients also use other medications
than dispensed drugs. Additional sources, such as in-hos-
pital medications, previously filled prescriptions (before
the study period), OTC sales, herbal and alternative rem-
edies, gifts and elicit Internet sales contribute to an under-
estimation of the total consumption of drugs. The absence
of in-hospital medications in our data have different
impact on different age groups, since the majority of the
in-hospital medications is given to elderly individuals.
Among additional sources, OTC-drugs are of special inter-
est, as previous studies have demonstrated a clear associa-
tion between the use of prescription drugs and OTC drugs
[10]. The vast majority of individuals over 65 use OTC
drugs regularly [30] and different studies have shown that
elderly people regularly use one OTC drug for every 2–3
prescribed drugs [30-32]. Applied on our data e.g., five
dispensed drugs should correspond to a total use of seven
drugs, OTC-drugs included.
Concomitantly taken multiple medications is a known
risk factor for the patient's health. Many dispensed drugs
are prescribed to be taken regularly. Some drugs, such as
certain analgesics, are meant to be taken temporarily only
when needed. Other drugs like antibiotics, are mostly
intended to be taken periodically; a quarter of all individ-
uals in Sweden in 2006 received one or more courses of
treatment of ATC J01 (Antibacterials for systemic use).
Periodically used drugs have different impact on the prev-
alence of multiple medications in different age groups.
Antibacterials for systemic use had a huge impact on the
prevalence of multiple medications in the age group 0–9,
but only a minor effect on the prevalence in the age
groups 70 and above. Antibacterials for systemic use were
The number of different dispensed drugs per individual related to age Figure 3
The number of different dispensed drugs per individual related to age. The number of different dispensed drugs per 
individual related to age in Sweden 2006 shown as box plots (median, Q1 and Q3 indicated). The 10th and 90th percentiles are 
shown at the end of the lines, (- - -) mark DP ≥ 5. Number of individuals = 6,146,679.BMC Clinical Pharmacology 2009, 9:11 http://www.biomedcentral.com/1472-6904/9/11
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the most commonly prescribed drugs for individuals in
the age group 0–9, but just one of many different used
drugs for elderly with multiple medications.
Another source of underestimation of multiple medica-
tions in our data was generic duplication of dispensed
drugs, recognised as a common problem in health care
[4,7,33]. We did not evaluate the number of duplicates for
each individual, but only calculated the number of dis-
pensed drugs comprised of different substances. If the
generic duplicate had been taken into account, it would
have resulted in an even larger prevalence of multiple
medications.
Methods to estimate multiple medications on a national 
level
Data of drug utilisation and multiple medications may be
available from the prescribers' medical records, pharmacy
registers, or from the patient. The medical record may be
preferable when to study the actual prescription orders,
whereas data from pharmacies provides a better picture of
what drug the patient actually received. Data collected
from individuals may be closer to the true exposure of
drugs, but are empirically associated with both intended
and unintended memory failures.
In the present study, we choose a cumulative method [18]
and counted all dispensed drugs, subsidized and non-sub-
sidized, for all individuals in all ages during a 12-month
period. Thereby, we compensated the monthly variation
of dispensed drugs during a year, which in Sweden in
2006 varied by more than 20% between different months.
A 12-month study period also includes all females with
prescribed sex hormones (ATC G03). Approximately three
quarter of all females with ATC G03 receives these drugs,
in contrast to other continually used drugs, for a 12-
month period at one single pharmacy visit. A shorter
study period, e.g. 3- or 6-month, will capture only a frac-
tion of the number of females with ATC G03.
The prevalence of one or more (DP ≥ 1) and five or more (DP ≥ 5) dispensed drugs in a 3-, 6- and 12- month study period Figure 4
The prevalence of one or more (DP ≥ 1) and five or more (DP ≥ 5) dispensed drugs in a 3-, 6- and 12- month 
study period. The prevalence (%) of DP ≥ 1 and DP ≥ 5 in a 3-, 6- and 12- month study period in Sweden in 2006. Number of 
individuals with DP ≥ 1 in the 3-month period = 4,108,730, in the 6-month period = 5,117,817 and in the 12-month period = 
6,146,679. Number of individuals with DP ≥ 5 in the 3-month period = 1,031,397, in the 6-month period = 1,569,180 and in the 
12-month period = 2,227,152.BMC Clinical Pharmacology 2009, 9:11 http://www.biomedcentral.com/1472-6904/9/11
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Our study shows that the length of a study period is essen-
tial for the estimation of the prevalence of the drug use
and multiple medications, especially for the younger age
groups. Compared to a study from Denmark based on a
sample from a large regional database over dispensed
drugs [8], we found a substantially higher prevalence of
drug use and multiple medications in an entire national
population. The difference between the results can partly
be explained by differences in methods of estimation; in
the Danish study were only subsidized prescription drugs
and drugs with established DDD included. Other contrib-
uting explanations were that DDD per 1,000 inhabitants
per day differs substantially between the countries [34],
and also that there were 14 years between the two studies,
1994 and 2006. The continued increase in the use of drugs
may therefore have influenced the estimates of the preva-
lence of DP ≥ 1 and DP ≥ 5. Compared to a study, based
on interviews with a sample of elderly in Sweden [35], our
observed prevalence for the age group was substantially
higher. Possible explanations to the difference might be a
minor difference in the definition of multiple drug use,
and also sample and interview bias. The presented preva-
lences in three other studies from Sweden, based on indi-
vidual register data of dispensed drugs [13-15], were close
to our findings, with the reservation that the observed
"polypharmacy" was not explicitly defined in one of the
studies [14].
Clinical relevance and implications
If the drug use and the occurrence of polypharmacy con-
tinue to increase, a future challenge for health care will be
to treat the resulting side effects. Therefore, the evaluation
and reconsideration of the drug therapy, especially for
patients who receive drugs via several different doctors,
should be a standard procedure before prescribing a new
drug. On an individual level, a prescriber seems to need
an overview of all the patients medications, including
other prescribers and OTC drugs and also earlier dis-
pensed "if needed drugs", to be able to optimize the
patient's treatment. Observed multiple medications for an
individual should serve as a warning signal, reminding
the prescriber that the number of dispensed drugs,
together with an uncertain number of drugs from addi-
tional sources, may be a risk factor for the patient's health.
Cost effects
The costs associated with drug-related problems have
been estimated to have more than doubled between 1995
and 2000 [36]. Moreover, the risk for drug-drug interac-
tions and adverse drug reactions are expected to increase
exponentially with the number of drugs consumed [9]. If
the current increase in the total drug consumption and
multiple medications will continue, there will be a con-
siderable risk of increased primary as well as secondary
costs for drug-related problems in the society. The rela-
tionship between the prevalence of multiple medications
and the cost for drug-related problems remains to be stud-
ied.
Conclusion
Our study of an entire national population demonstrated
that the prevalence of dispensed drugs and multiple med-
ications were extensive in all age groups and were higher
for females than for males. Consequently, rational and
irrational multiple medications should be regarded as a
risk factor in terms of potential drug-drug interactions and
Table 2: The prevalence of five or more (DP ≥ 5) dispensed drugs with and without ATC G031, J012 and N053.
All individuals DP ≥ 5F e m a l e s  D P  ≥ 5
All drugs ATC G03 excluded ATC J01 excluded ATC N05 excluded All drugs ATC G03 excluded
Age n = 2,227,152 2,131,961 1,997,440 2,111,966 1,356,934 1,262,497
0–9 6.6 6.6 3.6 6.5 5.7 5.7
10–19 6.2 5.2 4.3 5.9 8.3 6.4
20–29 9.9 8.3 7.5 9.1 15.2 11.8
30–39 13.9 12.5 11.2 12.8 19.7 16.7
40–49 18.4 17.4 15.9 16.8 23.8 21.8
50–59 30.2 28.9 27.4 28.3 36.3 33.5
60–69 42.3 41.1 39.4 40.4 46.8 44.4
70–79 62.4 61.6 60.0 60.2 65.5 64.1
80–89 75.1 74.7 73.2 72.7 77.3 76.7
90- 77.7 77.4 75.9 74.7 79.4 79.0
Total 24.4 23.4 21.9 23.2 29.6 27.5
The prevalence (%) of DP ≥ 5 for all individuals and for females, with and without ATC G03, J01, and N05 in Sweden in 2006.
1 Sex hormones and modulators of the genital system
2 Antibacterials for systemic use
3 PsycholepticsBMC Clinical Pharmacology 2009, 9:11 http://www.biomedcentral.com/1472-6904/9/11
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adverse drug reactions in all age groups. All sources of
medications and generic duplications taken into account,
the prevalence of multiple medications would be even
greater.
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